Molecular genetics and targeted therapeutics in biliary tract carcinoma

World Journal of Gastroenterology

Volumn 22, Issue 4, 2016, Pages 1335-1347

  Marks, Eric I ^a   Yee, Nelson S ^a,b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Biliary tract carcinoma; Cholangiocarcinoma; Gallbladder carcinoma; Molecular genetics; Personalized treatment; Precision therapy; Targeted therapy

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DABRAFENIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; LAPATINIB; ONARTUZUMAB; OXALIPLATIN; PANITUMUMAB; SELUMETINIB; SORAFENIB; TIVANTINIB; TRAMETINIB; TRASTUZUMAB; VEMURAFENIB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

AKT GENE; ARTICLE; BILE DUCT CARCINOMA; BILIARY EPITHELIUM; BRAF GENE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); EGFR GENE; GALLBLADDER CARCINOMA; GENE; GENE MUTATION; GENE TARGETING; GENETIC DISORDER; HER2 GENE; HUMAN; MAPK SIGNALING; MEK GENE; MET GENE; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MTOR GENE; MTOR SIGNALING; ONCOGENE K RAS; PERSONALIZED MEDICINE; PI3K GENE; PIK3CA GENE; TISSUE GROWTH; TISSUE SURVIVAL; TUMOR INVASION; VEGF GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MOLECULAR DIAGNOSIS; PATHOLOGY; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BIOMARKERS, TUMOR; CHOLANGIOCARCINOMA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; SIGNAL TRANSDUCTION;

EID: 84976372259     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/WJG.V22.I4.1335     Document Type: Article

References (103)

1. American Cancer Society. What are the key statistics about gallbladder cancer? Available from: URL: http://www.cancer.org/cancer/gallbladdercancer/detailedguide/gallbladder-key-statistics
2. Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist 2008; 13: 415-423 [PMID: 18448556 DOI: 10.1634/theoncologist.2007-0252]
3. Benson A, D’Angelica M, Abrams T, Are C, Bloomston PM, Chang D, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX. Hepatobiliary Cancers: National Comprehensive Cancer Network. Available from: URL: http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf
4. Silva MA, Tekin K, Aytekin F, Bramhall SR, Buckels JA, Mirza DF. Surgery for hilar cholangiocarcinoma; a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol 2005; 31: 533-539 [PMID: 15922889 DOI: 10.1016/j.ejso.2005.02.021]
5. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281 [PMID: 20375404 DOI: 10.1056/NEJMoa0908721]
6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29 [PMID: 25559415 DOI: 10.3322/caac.21254]
7. Hamilton SR, Aaltonen LA. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System 2000. Available from: URL: http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb2/BB2.pdf
8. Aishima S, Kubo Y, Tanaka Y, Oda Y. Histological features of precancerous and early cancerous lesions of biliary tract carcinoma. J Hepatobiliary Pancreat Sci 2014; 21: 448-452 [PMID: 24446428 DOI: 10.1002/jhbp.71]
9. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010; 28: 3531-3540 [PMID: 20547994 DOI: 10.1200/JCO.2009.27.4787]
10. Zen Y, Adsay NV, Bardadin K, Colombari R, Ferrell L, Haga H, Hong SM, Hytiroglou P, Klöppel G, Lauwers GY, van Leeuwen DJ, Notohara K, Oshima K, Quaglia A, Sasaki M, Sessa F, Suriawinata A, Tsui W, Atomi Y, Nakanuma Y. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 2007; 20: 701-709 [PMID: 17431410 DOI: 10.1038/modpathol.3800788]
11. Kawanishi S, Hiraku Y, Pinlaor S, Ma N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem 2006; 387: 365-372 [PMID: 16606333 DOI: 10.1515/BC.2006.049]
12. Aishima S, Mano Y, Tanaka Y, Kubo Y, Shirabe K, Maehara Y, Oda Y. Different roles of inducible nitric oxide synthase and cyclooxygenase-2 in carcinogenesis and metastasis of intrahepatic cholangiocarcinoma. Hum Pathol 2013; 44: 1031-1037 [PMID: 23260331 DOI: 10.1016/j.humpath.2012.09.004]
13. Sia D, Tovar V, Moeini A, Llovet JM. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene 2013; 32: 4861-4870 [PMID: 23318457 DOI: 10.1038/onc.2012.617]
14. Aishima S, Iguchi T, Fujita N, Taketomi A, Maehara Y, Tsuneyoshi M, Oda Y. Histological and immunohistological findings in biliary intraepithelial neoplasia arising from a background of chronic biliary disease compared with liver cirrhosis of non-biliary aetiology. Histopathology 2011; 59: 867-875 [PMID: 22092398 DOI: 10.1111/j.1365-2559.2011.04011.x]
15. Hsu M, Sasaki M, Igarashi S, Sato Y, Nakanuma Y. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer 2013; 119: 1669-1674 [PMID: 23335286 DOI: 10.1002/cncr.27955]
16. Nakanishi Y, Zen Y, Kondo S, Itoh T, Itatsu K, Nakanuma Y. Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm. Hum Pathol 2008; 39: 1153-1161 [PMID: 18495210 DOI: 10.1016/j.humpath.2007.11.018]
17. Furukawa T, Klöppel G, Volkan Adsay N, Albores-Saavedra J, Fukushima N, Horii A, Hruban RH, Kato Y, Klimstra DS, Longnecker DS, Lüttges J, Offerhaus GJ, Shimizu M, Sunamura M, Suriawinata A, Takaori K, Yonezawa S. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 2005; 447: 794-799 [PMID: 16088402 DOI: 10.1007/s00428-005-0039-7]
18. Schlitter AM, Born D, Bettstetter M, Specht K, Kim-Fuchs C, Riener MO, Jeliazkova P, Sipos B, Siveke JT, Terris B, Zen Y, Schuster T, Höfler H, Perren A, Klöppel G, Esposito I. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. Mod Pathol 2014; 27: 73-86 [PMID: 23828315 DOI: 10.1038/modpathol.2013.112]
19. Barreto SG, Dutt A, Chaudhary A. A genetic model for gallbladder carcinogenesis and its dissemination. Ann Oncol 2014; 25: 1086-1097 [PMID: 24705974 DOI: 10.1093/annonc/mdu006]
20. Tazuma S, Kajiyama G. Carcinogenesis of malignant lesions of the gall bladder. The impact of chronic inflammation and gallstones. Langenbecks Arch Surg 2001; 386: 224-229 [PMID: 11382326 DOI: 10.1007/s004230100220]
21. Legan M, Luzar B, Marolt VF, Cor A. Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions. World J Gastroenterol 2006; 12: 3425-3429 [PMID: 16733863 DOI: 10.3748/wjg.v12.i21.3425]
22. Wistuba II, Albores-Saavedra J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 1999; 6: 237-244 [PMID: 10526058 DOI: 10.1007/s005340050113]
23. Wistuba II, Maitra A, Carrasco R, Tang M, Troncoso P, Minna JD, Gazdar AF. High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma. Br J Cancer 2002; 87: 432-440 [PMID: 12177780 DOI: 10.1038/sj.bjc.6600490]
24. Chaube A, Tewari M, Garbyal RS, Singh U, Shukla HS. Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients manuscript id: 8962091628764582. BMC Cancer 2006; 6: 126 [PMID: 16686942 DOI: 10.1186/1471-2407-6-126]
25. Chang HJ, Kim SW, Kim YT, Kim WH. Loss of heterozygosity in dysplasia and carcinoma of the gallbladder. Mod Pathol 1999; 12: 763-769 [PMID: 10463477]
26. Wistuba II, Ashfaq R, Maitra A, Alvarez H, Riquelme E, Gazdar AF. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma. Am J Pathol 2002; 160: 2073-2079 [PMID: 12057912 DOI: 10.1016/S0002-9440(10)61157-1]
27. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7 Suppl 4: 2-8 [PMID: 12202782 DOI: 10.1634/theoncologist.7-suppl_4-2]
28. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008; 98: 418-425 [PMID: 18087285 DOI: 10.1038/sj.bjc.6604129]
29. Chang YT, Chang MC, Huang KW, Tung CC, Hsu C, Wong JM. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan. J Gastroenterol Hepatol 2014; 29: 1119-1125 [PMID: 24372748 DOI: 10.1111/jgh.12505]
30. Gwak GY, Yoon JH, Shin CM, Ahn YJ, Chung JK, Kim YA, Kim TY, Lee HS. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 2005; 131: 649-652 [PMID: 16032426 DOI: 10.1007/s00432-005-0016-1]
31. Zaczek A, Brandt B, Bielawski KP. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 2005; 20: 1005-1015 [PMID: 15944951]
32. Giatromanolaki A, Sivridis E, Simopoulos C, Polychronidis A, Gatter KC, Harris AL, Koukourakis MI. Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas. J Surg Oncol 2006; 94: 242-247 [PMID: 16900513 DOI: 10.1002/jso.20443]
33. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000; 5 Suppl 1: 3-10 [PMID: 10804084 DOI: 10.1634/theoncologist.5-suppl_1-3]
34. Tian Y, Ding RY, Zhi YH, Guo RX, Wu SD. Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J Gastroenterol 2006; 12: 415-419 [PMID: 16489641 DOI: 10.3748/wjg.v12.i3.415]
35. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002; 13: 41-59 [PMID: 11750879 DOI: 10.1016/S1359-6101(01)00029-6]
36. Yang L, Guo T, Jiang S, Yang Z. Expression of ezrin, HGF and c-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder. Hepatogastroenterology 2012; 59: 1769-1775 [PMID: 22172411]
37. Moon WS, Park HS, Lee H, Pai R, Tarnawski AS, Kim KR, Jang KY. Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer. Cancer Res Treat 2005; 37: 171-176 [PMID: 19956499 DOI: 10.4143/crt.2005.37.3.171]
38. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284 [PMID: 17126425]
39. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003; 52: 706-712 [PMID: 12692057 DOI: 10.1136/gut.52.5.706]
40. Saetta AA, Papanastasiou P, Michalopoulos NV, Gigelou F, Korkolopoulou P, Bei T, Patsouris E. Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch 2004; 445: 179-182 [PMID: 15221372 DOI: 10.1007/s00428-004-1046-9]
41. Goldenberg D, Rosenbaum E, Argani P, Wistuba II, Sidransky D, Thuluvath PJ, Hidalgo M, Califano J, Maitra A. The V599E BRAF mutation is uncommon in biliary tract cancers. Mod Pathol 2004; 17: 1386-1391 [PMID: 15181454 DOI: 10.1038/modpathol.3800204]
42. Hansel DE, Rahman A, Hidalgo M, Thuluvath PJ, Lillemoe KD, Shulick R, Ku JL, Park JG, Miyazaki K, Ashfaq R, Wistuba II, Varma R, Hawthorne L, Geradts J, Argani P, Maitra A. Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 2003; 163: 217-229 [PMID: 12819026 DOI: 10.1016/S0002-9440(10)63645-0]
43. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-1321 [PMID: 9812896 DOI: 10.1126/science.282.5392.1318]
44. Thant AA, Nawa A, Kikkawa F, Ichigotani Y, Zhang Y, Sein TT, Amin AR, Hamaguchi M. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3KAkt pathways in ovarian cancer cells. Clin Exp Metastasis 2000; 18: 423-428 [PMID: 11467775 DOI: 10.1023/A:]
45. Riener MO, Bawohl M, Clavien PA, Jochum W. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer 2008; 47: 363-367 [PMID: 18181165 DOI: 10.1002/gcc.20540]
46. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-5510 [PMID: 18794884 DOI: 10.1038/onc.2008.245]
47. Geynisman DM, Catenacci DV. Toward personalized treatment of advanced biliary tract cancers. Discov Med 2012; 14: 41-57 [PMID: 22846202]
48. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35 [PMID: 21157483 DOI: 10.1038/nrm3025]
49. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7: 763-777 [PMID: 17882277 DOI: 10.1038/nrc2222]
50. Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, Gruenberger B, Gruenberger T, Pirker R, Filipits M. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 2007; 13: 4795-4799 [PMID: 17699857 DOI: 10.1158/1078-0432.CCR-07-0738]
51. Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 1994; 9: 462-467 [PMID: 7827297 DOI: 10.1111/j.1440-1746.1994.tb01275.x]
52. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 2005; 128: 2054-2065 [PMID: 15940637 DOI: 10.1053/j.gastro.2005.03.010]
53. Sugiyama H, Onuki K, Ishige K, Baba N, Ueda T, Matsuda S, Takeuchi K, Onodera M, Nakanuma Y, Yamato M, Yamamoto M, Hyodo I, Shoda J. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. J Gastroenterol 2011; 46: 779-789 [PMID: 21331764 DOI: 10.1007/s00535-011-0380-3]
54. Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carty SE. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 1998; 227: 398-404 [PMID: 9527063 DOI: 10.1097/0000065 8-199803000-00012]
55. Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, Gores GJ. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 2007; 132: 384-396 [PMID: 17241887 DOI: 10.1053/j.gastro.2006.10.037]
56. Zhi YH, Liu RS, Song MM, Tian Y, Long J, Tu W, Guo RX. Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. World J Gastroenterol 2005; 11: 3724-3728 [PMID: 15968728 DOI: 10.3748/wjg.v11.i24.3724]
57. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-3340 [PMID: 9096394 DOI: 10.1073/pnas.94.7.3336]
58. Kim H, Song JY, Cho JY, Yoon YS, Han HS, Lee HS, Ryu HS, Choe G. Strong cytoplasmic expression of COX2 at the invasive fronts of gallbladder cancer is associated with a poor prognosis. J Clin Pathol 2010; 63: 1048-1053 [PMID: 20924037 DOI: 10.1136/jcp.2010.080713]
59. Zhang Z, Lai GH, Sirica AE. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 2004; 39: 1028-1037 [PMID: 15057907 DOI: 10.1002/hep.20143]
60. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006; 24: 3069-3074 [PMID: 16809731 DOI: 10.1200/JCO.2005.05.3579]
61. Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, Shin DB, Kang HJ, Sun JM, Park JO, Park YS, Kang WK, Lim HY. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012; 13: 181-188 [PMID: 22192731 DOI: 10.1016/S1470-2045(11)70301-1]
62. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 2010; 28: 3491-3497 [PMID: 20530271 DOI: 10.1200/JCO.2010.28.4075]
63. Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 2014; 15: 819-828 [PMID: 24852116 DOI: 10.1016/S1470-2045(14)70212-8]
64. Sohal DP, Mykulowycz K, Uehara T, Teitelbaum UR, Damjanov N, Giantonio BJ, Carberry M, Wissel P, Jacobs-Small M, O’Dwyer PJ, Sepulveda A, Sun W. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol 2013; 24: 3061-3065 [PMID: 24146220 DOI: 10.1093/annonc/mdt416]
65. Jensen LH, Lindebjerg J, Ploen J, Hansen TF, Jakobsen A. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Ann Oncol 2012; 23: 2341-2346 [PMID: 22367707 DOI: 10.1093/annonc/mds008]
66. Paul B, Trovato JA, Thompson J. Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. Am J Health Syst Pharm 2008; 65: 1703-1710 [PMID: 18768996 DOI: 10.2146/ajhp070646]
67. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009; 64: 777-783 [PMID: 19169683 DOI: 10.1007/s00280-009-0927-7]
68. Peck J, Wei L, Zalupski M, O’Neil B, Villalona Calero M, Bekaii-Saab T. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology 2012; 82: 175-179 [PMID: 22433475 DOI: 10.1159/000336488]
69. Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 2010; 10: 631 [PMID: 21087480 DOI: 10.1186/1471-2407-10-631]
70. Sorscher S. Marked radiographic response of a HER-2overexpressing biliary cancer to trastuzumab. Cancer Manag Res 2013; 9: 1-3 [PMID: 24376362 DOI: 10.2147/CMAR.S55091]
71. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010; 11: 48-54 [PMID: 19932054 DOI: 10.1016/S1470-2045(09)70333-X]
72. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007; 13: 1576-1583 [PMID: 17332304 DOI: 10.1158/1078-0432.CCR-06-1150]
73. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O’Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 2011; 29: 2357-2363 [PMID: 21519026 DOI: 10.1200/JCO.2010.33.9473]
74. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439: 358-362 [PMID: 16273091 DOI: 10.1038/nature04304]
75. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006; 407: 597-612 [PMID: 16757355 DOI: 10.1016/S0076-6879(05)07047-3]
76. Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, Del Giovane C, Luppi G, Conte P. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010; 102: 68-72 [PMID: 19935794 DOI: 10.1038/sj.bjc.6605458]
77. Lee JK, Capanu M, O’Reilly EM, Ma J, Chou JF, Shia J, Katz SS, Gansukh B, Reidy-Lagunes D, Segal NH, Yu KH, Chung KY, Saltz LB, Abou-Alfa GK. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. Br J Cancer 2013; 109: 915-919 [PMID: 23900219 DOI: 10.1038/bjc.2013.432]
78. LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K, Robinson E, Lubner SJ. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs 2013; 31: 943-948 [PMID: 23263993 DOI: 10.1007/s10637-012-9916-5]
79. Kim do H, Jeong YI, Chung CW, Kim CH, Kwak TW, Lee HM, Kang DH. Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells. Int J Nanomedicine 2013; 8: 1697-1711 [PMID: 23658488]
80. Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, Moon YS, Yaqubie A, Kelly N, Le DT, Lipson EJ, Chapman PB, Diaz LA, Vogelstein B, Nowak MA. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2013; 2: e00747 [PMID: 23805382 DOI: 10.7554/eLife.00747]
81. Isomoto H. Epigenetic alterations associated with cholangiocarcinoma (review). Oncol Rep 2009; 22: 227-232 [PMID: 19578760 DOI: 10.3892/or_00000428]
82. Takahashi R, Yoshitomi M, Yutani S, Shirahama T, Noguchi M, Yamada A, Itoh K, Sasada T. Current status of immunotherapy for the treatment of biliary tract cancer. Hum Vaccin Immunother 2013; 9: 1069-1072 [PMID: 23376808 DOI: 10.4161/hv.23844]
83. Aruga A, Takeshita N, Kotera Y, Okuyama R, Matsushita N, Ohta T, Takeda K, Yamamoto M. Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer. J Transl Med 2014; 12: 61 [PMID: 24606884 DOI: 10.1186/1479-5876-12-61]
84. Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, Venesio T, Capussotti L, Risio M, Aglietta M. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 2006; 12: 1680-1685 [PMID: 16551849 DOI: 10.1158/1078-0432.CCR-05-1692]
85. Voss JS, Holtegaard LM, Kerr SE, Fritcher EG, Roberts LR, Gores GJ, Zhang J, Highsmith WE, Halling KC, Kipp BR. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol 2013; 44: 1216-1222 [PMID: 23391413 DOI: 10.1016/j.humpath.2012.11.006]
86. Rizvi S, Borad MJ, Patel T, Gores GJ. Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin Liver Dis 2014; 34: 456-464 [PMID: 25369307 DOI: 10.1055/s-0034-1394144]
87. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013; 144: 829-840 [PMID: 23295441 DOI: 10.1053/j.gastro.2013.01.001]
88. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994; 14: 109-114 [PMID: 8047893 DOI: 10.1055/s-2007-1007302]
89. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013; 145: 1215-1229 [PMID: 24140396 DOI: 10.1053/j.gastro.2013.10.013]
90. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014; 383: 2168-2179 [PMID: 24581682 DOI: 10.1016/S0140-6736(13)61903-0]
91. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995; 75: 171-190 [PMID: 8000995 DOI: 10.1002/1097-0142(19950101)75:1]
92. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 2014; 6: 99-109 [PMID: 24634588]
93. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 2005; 206: 356-365 [PMID: 15892172 DOI: 10.1002/path.1779]
94. Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol 1998; 29: 175-180 [PMID: 9490278 DOI: 10.1016/S0046-8177(98)90229-5]
95. Rashid A, Ueki T, Gao YT, Houlihan PS, Wallace C, Wang BS, Shen MC, Deng J, Hsing AW. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res 2002; 8: 3156-3163 [PMID: 12374683]
96. Hanada K, Tsuchida A, Iwao T, Eguchi N, Sasaki T, Morinaka K, Matsubara K, Kawasaki Y, Yamamoto S, Kajiyama G. Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 1999; 94: 1638-1642 [PMID: 10364037 DOI: 10.1111/j.1572-0241.1999.01155.x]
97. Suto T, Habano W, Sugai T, Uesugi N, Funato O, Kanno S, Saito K, Nakamura Si. Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer. J Surg Oncol 2000; 73: 158-163 [PMID: 10738270 DOI: 10.1002/(SICI)1096-9098(200003)73]
98. Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Köckerling F, Hauss J, Wittekind C. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000; 47: 721-727 [PMID: 11034592 DOI: 10.1136/gut.47.5.721]
99. Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX, Hezel AF. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer 2011; 11: 60 [PMID: 21303542 DOI: 10.1186/1471-2407-11-60]
100. Weiss GA, Rossi MR, Khushalani NI, Lo K, Gibbs JF, Bharthuar A, Cowell JK, Iyer R. Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma. J Gastrointest Oncol 2013; 4: 20-29 [PMID: 23450128]
101. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012; 17: 72-79 [PMID: 22180306 DOI: 10.1634/theoncologist.2011-0386]
102. Riener MO, Bawohl M, Clavien PA, Jochum W. Analysis of oncogenic AKT1 p.E17K mutation in carcinomas of the biliary tract and liver. Br J Cancer 2008; 99: 836 [PMID: 18728674 DOI: 10.1038/sj.bjc.6604498]
103. Leal P, García P, Sandoval A, Letelier P, Brebi P, Ili C, Álvarez H, Tapia O, Roa JC. Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma. Arch Pathol Lab Med 2013; 137: 552-557 [PMID: 23544944 DOI: 10.5858/arpa.2012-0032-OA]